<code id='497181B0A3'></code><style id='497181B0A3'></style>
    • <acronym id='497181B0A3'></acronym>
      <center id='497181B0A3'><center id='497181B0A3'><tfoot id='497181B0A3'></tfoot></center><abbr id='497181B0A3'><dir id='497181B0A3'><tfoot id='497181B0A3'></tfoot><noframes id='497181B0A3'>

    • <optgroup id='497181B0A3'><strike id='497181B0A3'><sup id='497181B0A3'></sup></strike><code id='497181B0A3'></code></optgroup>
        1. <b id='497181B0A3'><label id='497181B0A3'><select id='497181B0A3'><dt id='497181B0A3'><span id='497181B0A3'></span></dt></select></label></b><u id='497181B0A3'></u>
          <i id='497181B0A3'><strike id='497181B0A3'><tt id='497181B0A3'><pre id='497181B0A3'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:15
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          United colonoscopy coverage change 'may cost lives,' doctors say
          United colonoscopy coverage change 'may cost lives,' doctors say

          AdobeWhengastroenterologistslearnedinMarchthatUnitedHealthcareplanstobarricademanycolonoscopiesbehin

          read more
          Wegovy’s successful heart trial raises vital question about weight loss
          Wegovy’s successful heart trial raises vital question about weight loss

          BloombergAlandmarkstudythatfoundtheblockbusterobesitydrugWegovyreducesthechanceofheartproblemsaddsur

          read more
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum
          New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

          CMSAdministratorChiquitaBrooks-LaSureChipSomodevilla/GettyImagesWASHINGTON— EliLilly’slatestanti-amy

          read more

          The best solution to the drug shortages problem

          AdobeDrugshortagesintheUnitedStatesareatarecordhigh.Atleast14essentialgenericcancerdrugsarecurrently